The effect of Urtica Dioica (Nettle), Vaccinium myrtillus on blood glucose parameters and lipid profile in patients with type 2 diabetes: a double-blind clinical trial

Determining the effect of Urtica Dioica, Vaccinium myrtillus on blood glucose parameters and lipid profile in patients with type 2 diabetes

Double-blind randomized clinical trial with two groups: Urtica Dioica, Vaccinium myrtillus, and placebo

The study will be conducted at Imam Reza Hospital. Patients will be randomly divided into two groups of Urtica Dioica, Vaccinium myrtillus, and placebo by block method. The researchers and participants will not be aware of the groups involved).

Type 2 diabetes, Taking hypoglycemic drugs, Age 40-70 years, Body mass index 18.5–30 kg / m 2, Fasting blood sugar equal to or more than 126 mg / d exclusion criteria: Type 1 diabetes, Other specific types of diabetes, Insulin therapy over the past three months, Having serious gastrointestinal diseases (GI), Have a history of diabetic ketoacidosis, non-ketotic hyperosmolar diabetic coma, severe infection or surgery in the previous month, Uncontrolled high blood pressure, mental illness, Abuse or addiction to alcohol, psychoactive substances or other drugs, Pregnancy, lactation or plan to become pregnant, Having cardiovascular disease, renal insufficiency, liver dysfunction, thyroid dysfunction, parathyroid dysfunction, and cancers, High physical activity, Chronic complications of diabetes (neuropathy, retinopathy, according to patient records), diabetic nephropathy, hypothyroidism and hyperthyroidism, Sensitivity to nettle, Vaccinium myrtillus

The Urtica Dioica, Vaccinium myrtillus recipient will receive a capsule (500 mg) containing 300 mg of Urtica Dioica and 150 mg Vaccinium myrtillus every 12 hours. The placebo group will receive a 500 mg placebo capsule every 12 hours.

Fasting blood sugar amount that will be checked with blood tests before starting the drug and three months later

Impossibility to provide the drugs through the company due to coronary conditions

Samples will be randomly assigned to four blocks using Random Allocation Software. Blocking and allocation sequences for concealment will be done by the non-involved researcher (Allocation Concealment). The sample allocation ratio will be Allocation 1:1 and will be divided into two groups of receiving Urtica Dioica, Vaccinium myrtillus, and Placebo. Then based on blocks and allocation sequences each client will be given white pockets that are prepared in equal sizes and on which the numbers 1 to 60 are written (in order of allocation sequence). The pockets will contain white boxes containing Urtica Dioica, Vaccinium myrtillus, or Placebo capsules. Only the person in charge of packing Urtica Dioica, Vaccinium myrtillus, and Placebo capsules will know the numbers of the relevant pockets and none of the researchers or patients will know the type of medicine that each person receives. The first person will be given pocket number 1 and then it will continue until completion. Urtica Dioica, Vaccinium myrtillus, and placebo capsules will be similar in shape, size, color and, smell

Based on blocks and allocation sequences each client will be given white pockets that are prepared in equal sizes and on which the numbers 1 to 60 are written (in order of allocation sequence). The pockets will contain white boxes containing Urtica Dioica, Vaccinium myrtillus, or Placebo capsules. Only the person in charge of packing Urtica Dioica, Vaccinium myrtillus, and Placebo capsules will know the numbers of the relevant pockets and none of the researchers or patients will know the type of medicine that each person receives. The first person will be given pocket number 1 and then it will continue until completion. Urtica Dioica, Vaccinium myrtillus, and placebo capsules will be similar in shape, size, color, and smell.

No more information